[Clinical biochemical bases for using terrilitin in ENT diseases].
D000681:Amylases / Q000627:therapeutic use*; D001230:Aspergillus / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004789:Enzyme Activation / Q000187:drug effects; D057487:Enzyme Therapy; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D006868:Hydrolysis; D066298:In Vitro Techniques; D010038:Otorhinolaryngologic Diseases / Q000097:blood / Q000188:drug therapy*; D010447:Peptide Hydrolases / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000494:pharmacology; D013696:Temperature; D014357:Trypsin / Q000627:therapeutic use
D004338:Drug Combinations; D011480:Protease Inhibitors; C009402:amylase, phosphates, proteases drug combinations; D000681:Amylases; D010447:Peptide Hydrolases; D014357:Trypsin
Kliniko-biokhimicheskie obosnovaniia primeneniia terrilitina pri LOR-zabolevaniiakh.